8-K: Lantern Pharma Announces Year-End 2024 Financial Results and Business Updates, Highlighting AI-Driven Drug Development Progress

Lantern Pharma reports year-end 2024 financial results and provides business updates, emphasizing advancements in its AI-driven drug development programs and clinical trial progress.

Summary

• Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company highlighted the progress of its AI-driven drug development programs and the RADR AI platform.
• Key clinical programs, including LP-300, LP-184, and LP-284, are actively enrolling patients.
• The HARMONIC trial for LP-300 showed an 86% clinical benefit rate and a 43% objective response rate in never-smoker NSCLC patients.
• LP-184 received two FDA Fast Track Designations and three Rare Pediatric Disease Designations.
• The RADR AI platform surpassed 100 billion oncology-specific data points.
• Cash, cash equivalents, and marketable securities totaled approximately $24 million as of December 31, 2024.
• The company reported a net loss of approximately $5.9 million (or $0.54 per share) for the quarter ended December 31, 2024, compared to a net loss of approximately $4.2 million (or $0.39 per share) for the quarter ended December 31, 2023.
• Net loss was $1.93 per share for the fiscal year 2024 compared to $1.47 per share for the fiscal year 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is making progress in its clinical trials and AI platform development, the increased net loss and decreased cash reserves are concerning.

Positives

• LP-300 showed promising clinical benefit and objective response rates in never-smoker NSCLC patients.
• LP-184 received multiple FDA designations, enhancing its market potential.
• LP-184 demonstrated synergy with checkpoint inhibitors, potentially expanding its therapeutic applications.
• The RADR AI platform continues to advance drug candidate optimization and biomarker discovery.
• Lantern secured Japanese Patent Office protection for LP-284, extending IP coverage through 2039.
• Starlight Therapeutics made strides in developing therapies for CNS and brain cancers.

Negatives

• The company reported a net loss of approximately $5.9 million (or $0.54 per share) for the quarter ended December 31, 2024, compared to a net loss of approximately $4.2 million (or $0.39 per share) for the quarter ended December 31, 2023.
• Net loss was $1.93 per share for the fiscal year 2024 compared to $1.47 per share for the fiscal year 2023.
• Cash reserves decreased from approximately $41.3 million as of December 31, 2023, to approximately $24.0 million as of December 31, 2024.

Risks

• The company may not be able to secure sufficient future funding to advance its clinical trials and operations.
• Observations in preclinical and early clinical studies may not ensure consistent or successful later development.
• Research efforts and collaborations may not be successful.
• The company may not be successful in licensing potential candidates or completing partnerships.
• None of the product candidates have received FDA marketing approval.
• No drug product based on the RADR AI platform has received FDA marketing approval.

Future Outlook

Lantern Pharma expects to have meaningful clinical readouts from its Phase 1 and Phase 2 programs during 2025 and continue to launch innovative AI modules to accelerate drug development in oncology.

Management Comments

• Lantern is a leader in the development of tech-bio to deliver the next generation of cancer medicines, where success is defined by both AI-driven progress and meaningful patient outcomes, said Panna Sharma, CEO & President of Lantern Pharma.
• During 2025, we expect to have meaningful clinical readouts from our Phase 1 and Phase 2 programs and continue to launch highly innovative AI modules that can be used to accelerate and transform drug development in oncology.

Industry Context

Lantern Pharma's focus on AI-driven drug discovery aligns with the growing trend of leveraging artificial intelligence and machine learning to improve the efficiency and effectiveness of oncology drug development. The company's RADR platform and collaborations with other companies in the space position it to potentially capitalize on this trend.

Comparison to Industry Standards

• Lantern Pharma's AI-driven approach to drug discovery aims to reduce development timelines by 30-50% and preclinical costs by up to 60% compared to traditional ADC development, which is a significant improvement if achieved.
• The company's BBB permeability prediction algorithm holds five of the top ten positions on the Therapeutic Data Commons Leaderboard, indicating a competitive advantage in CNS therapeutic development.
• Other companies like Recursion Pharmaceuticals and Exscientia are also leveraging AI for drug discovery, but Lantern's focus on oncology and its RADR platform differentiate it.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased cash reserves.
• Positive clinical trial results and FDA designations could positively impact shareholder value.
• Employees are likely to be motivated by the progress in drug development and the company's AI platform.
• Patients could benefit from the development of new therapies for cancer.

Next Steps

• Lantern plans to share additional results from the LP-300 expansion cohort in Q2 2025.
• The LP-184 Phase 1a trial is targeted to finish enrollment during Q2 2025.
• Lantern expects to initiate a Phase 1b/2 study in TNBC evaluating a combination regimen with Olaparib, subject to clinical priorities and funding.
• An investigator-led study of LP-184 for recurrent bladder cancer is planned to begin in Denmark.
• Lantern plans on sharing data from early preclinical studies of LP-284 during Q2 of 2025.
• Lantern expects to publicly release multiple modules (validated A.I. frameworks) that can be accessed by Lantern collaborators for specific needs in oncology drug development.

Key Dates

Keywords

Lantern Pharma, AI, RADR, Oncology, Drug Development, Clinical Trials, LP-300, LP-184, LP-284, Financial Results